Navigation Links
Experts Compare Colon Cancer Treatment Outcomes

Review of studies shows big survival gains

THURSDAY, Sept. 20 (HealthDay News) -- The current chemotherapy regimens of irinotecan, oxaliplatin, and molecular-targeted treatments are helping patients with advanced colorectal cancer live several months longer than they did a few years ago, when these therapies weren't available, Greek researchers say.

Researchers at the University of Ioannina School of Medicine performed a meta-analysis of 242 studies on these chemotherapies, conducted over the past 40 years.

The study was published online Thursday in The Lancet Oncology journal.

Previous studies have noted survival benefits for patients receiving the newer regimens, but the degree of these benefits across assorted regimens has been less clear, the team said.

They conducted the meta-analysis to examine whether certain treatment regimens for advanced colorectal cancer offer better survival and delayed disease progression and to determine the extent of such benefits.

According to the study, among patients who would be expected to live for one year when treated with the drugs fluorouracil and leucovorin, there was an estimated absolute survival benefit of an extra eight months if patients received additional treatment with irinotecan plus bevacizumab.

The researchers also concluded that the addition of oxaliplatin plus bevacizumab or irinotecan plus oxaliplatin offered four to seven additional months of survival for patients.

However, the researchers also noted that multidrug combinations that improve survival can cause serious toxic side effects. They called for long-term follow-up data on toxicity associated with these treatments.

"The fluorouracil, leucovorin, irinotecan, plus bevacizumab regimen especially, which has the highest probability to be the best in improving survival according to our analysis, might be complicated by up to 84.9 percent of grade 3 or 4 adverse events, including a 1.5 percent chance of gastrointestinal perforation," the researchers noted. "(These) existing uncertainties suggest that more data are needed, especially for the newest regimens", they said.

More information

The American Cancer Society has more about colorectal cancer treatment decisions.

-- Robert Preidt

SOURCE: The Lancet Oncology, news release, Sept. 20, 2007

Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Smoking a greater risk than HIV? Yes say health experts!!!!
2. Good carb, bad carb? Experts debate.
3. Serevent, to be examined by experts due to deaths associated with its use
4. Spread Of Rocky Mountain Spotted Fever Is A Probability, Say Experts
5. Experts Recommend Preventive Measures For Avian Flu To Begin From Farms
6. Experts Insist That Neonatal Herpes Be Reported Regularly
7. Experts State Strategies To Increase Good Cholesterol
8. Speed up bird flu vaccine, Bush tells experts
9. Tennis elbow not new among cricketers, say experts
10. Cancer Can Recur Any Time, Experts Caution
11. Experts Building Bird Flu Warning System
Post Your Comments:
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... in the 1980s we have seen vast improvements in scientific research and discoveries, ... significant strides, providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), ... at the Radiological Society of North America (RSNA) 2015 annual meeting through December ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of aesthetic and ... to the devices for sale in the United States. Clarity is a Superior ... nm Nd:YAG lasers, into a single platform that is easy to own and operate. ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... and SACC-USA through membership and leadership since 2008. Gary Bruce, President of PartnerTech ... . Gary has spent a significant amount of time in Sweden since joining ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , December 1, 2015 ... new market research report "Nucleic Acid Labeling Market by ... Nick Translation, Random Primer, In Vitro Transcription, Reverse Transcription, ... published by MarketsandMarkets, The global market is expected to ... Million in 2015, growing at a CAGR of 8.65%. ...
(Date:12/1/2015)... , December 1, 2015 Russia ... clinical trials. 70% of new drugs registered in Europe ... Russia . --> Russia has always been ... of new drugs registered in Europe in 2015 ... --> Russia has always been a country ...
(Date:12/1/2015)... 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... announced today that the company will present at the LD ... at the Luxe Sunset Boulevard Hotel in Los ... Relmada Therapeutics, will present on Thursday, December 3, at 9:00 ... . Please register at least 10 minutes prior to the ...
Breaking Medicine Technology: